Advertisement

Topics

BioMarker Strategies, LLC Company Profile

00:18 EDT 25th June 2018 | BioPortfolio

BioMarker Strategies has developed SnapPath®, the only cancer diagnostics system that automates and standardizes functional ex vivo profiling of live solid tumor cells from fresh biopsies or other fresh, unfixed samples such as xenografts or tumorgrafts. SnapPath® can help guide cancer drug development and treatment selection. The Company’s PathMAP® Functional Signaling Profiles, created using the SnapPath® system, represent a new class of biomarker tests that are highly predictive of individual response to targeted treatment. PathMAP® Melanoma is currently in development as a companion diagnostic under a National Cancer Institute SBIR Phase II contract, the ultimate goal of which is to prepare for a clinical trial of PathMAP® Melanoma under a Phase IIB NCI contract. Patents for SnapPath® have been allowed and are proceeding to grant in Europe and Australia, and applications are pending in the U.S. and other countries. Patents for PathMAP® Functional Signaling Profiles have been allowed and are proceeding to grant in Australia and Singapore, and applications are pending in Europe, the U.S. and other countries. For more information about BioMarker Strategies, please see www.biomarkerstrategies.com.


News Articles [365 Associated News Articles listed on BioPortfolio]

Critical Path Institute receives regulatory support for liver injury biomarker

(Critical Path Institute (C-Path)) The European Medicines Agency (EMA) issued a Letter of Support to C-Path's Predictive Safety Testing Consortium and Duchenne Regulatory Science Consortium for measur...

PD-L1 biomarker makes a comeback in bladder cancer

PD-L1 has long been dismissed as a viable biomarker in advanced bladder cancer, given that numerous late-stage clinical trials of...Read More... The post PD-L1 biomarker makes a comeback in bladder ca...

CTCs as a Predictive Biomarker in Suspected Ovarian Cancer

Might circulating tumor cells be useful as a diagnostic biomarker in women with complex pelvic masses? Laboratory Medicine

TMB as New Biomarker in NSCLC -- Ready for Clinic?

A new biomarker -- high tumor mutational burden (TMB) -- identifies lung cancer patients who do better on immunotherapy than on chemotherapy. Medscape Medical News

Is This New Immunotherapy Biomarker Really 'Ready for Primetime'?

Drs West and Borghaei discuss the current state of tumor mutational burden as a potential biomarker for lung cancer. Medscape Oncology

No Silver-Bullet Biomarker for Precision RCC Care

Bryant FurlowJun 2, 2018No one molecular biomarker is likely to guide treatment of RCC in the foreseeable future. Multipredictor models might be a way forward, an expert concluded.

Determining the Optimal Biomarker Frequency for Biosensors

Chi-En Lin won Metrohm’s Young Chemist of the Year award for his research into optimal biomarker frequencies, not just the novelty of the research but how it can be applied. Determining optimal biom...

ASCO 2018: Roche discusses TMB as a predictive biomarker for NSCLC

Data from B-F1RST (NCT02848651), the first prospective study of blood tumor mutational burden (bTMB) as a biomarker for Roche’s Tecentriq...Read More... The post ASCO 2018: Roche discusses TMB as a ...

Drugs and Medications [10 Associated Drugs and Medications listed on BioPortfolio]

Plavix [Rebel Distributors Corp]

These highlights do not include all the information needed to use PLAVIX safely and effectively. See full prescribing information for PLAVIX.   PLAVIX (clopidogrel bisulfate) tablets Initial U.S. App...

Plavix [Contract Pharmacy Services-PA]

These highlights do not include all the information needed to use PLAVIX safely and effectively. See full prescribing information for PLAVIX.   PLAVIX (clopidogrel bisulfate) tablets Initial U.S. App...

Plavix [State of Florida DOH Central Pharmacy]

These highlights do not include all the information needed to use PLAVIX safely and effectively. See full prescribing information for PLAVIX.   PLAVIX (clopidogrel bisulfate) tablets Initial U.S. App...

Plavix [Physicians Total Care, Inc.]

These highlights do not include all the information needed to use PLAVIX safely and effectively. See full prescribing information for PLAVIX.   PLAVIX (clopidogrel bisulfate) tablets Initial U.S. App...

Plavix [Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership]

These highlights do not include all the information needed to use PLAVIX safely and effectively. See full prescribing information for PLAVIX.   PLAVIX (clopidogrel bisulfate) tablets Initial U.S. App...

PubMed Articles [1157 Associated PubMed Articles listed on BioPortfolio]

Combination Strategies PD-1/PD-L1 Antagonists.

Despite the broad clinical antitumor activity of PD-1/PD-L1 antagonists, many patients who are treated with these agents either do not respond or achieve suboptimal responses. Improving overall outcom...

Strategies to decrease oxidative stress biomarker levels in human medical conditions: A meta-analysis on 8-iso-prostaglandin F.

The widespread detection of elevated oxidative stress levels in many medical conditions has led to numerous efforts to design interventions to reduce its effects. Efforts have been wide-ranging, from ...

Feasibility of using urinary TDGA as a biomarker for VCM exposures.

Thiodiglycolic acid (TDGA) is a major metabolite of vinyl chloride monomer (VCM), and it has been suggested as an exposure biomarker for VCM. The validity of this biomarker when the level of VCM is le...

Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.

Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as a tumor biomarker is relatively low because plasma Cg...

Integrated Multi-Omic Predictors for Ovarian Cancer Survival.

Increasingly affordable high-throughput molecular profiling technologies have made feasible the measurement of omics-wide interindividual variations for the purposes of predicting cancer prognosis. Wh...

Clinical Trials [3207 Associated Clinical Trials listed on BioPortfolio]

Evidence-based Screening Strategies for Celiac Disease

Main aim: To find evidence-based screening strategies for celiac disease in high risk groups and to find new biomarkers or biomarker combinations for celiac disease diagnostics and follow-...

Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients

This clinical trial studies normal breast tissue changes combined with breast magnetic resonance imaging (MRI) that may suggest the beginnings of cancer development. Using breast tissue ma...

Biomarker for Hurler Disease

Development of a new MS-based biomarker for the early and sensitive diagnosis of Hurler disease from plasma. Testing for clinical robustness, specificity and long-term stability of the bio...

Strategies to Enhance the Experience of Exercise

This study aims to test the effect of three cognitive strategies to affect individuals' subjective experience of cardiovascular exercise. Participants will be randomly assigned to one of t...

Guiding Evidence Based Therapy Using Biomarker Intensified Treatment

The primary objective is to determine the efficacy of a strategy of biomarker-guided therapy compared with usual care in high risk patients with left ventricular systolic dysfunction.

Companies [624 Associated Companies listed on BioPortfolio]

BioMarker Strategies LLC

BioMarker Strategies is a privately-held molecular diagnostics company founded in 2006 at The Johns Hopkins Science & Technology Park in Baltimore, and now based in Rockville, Mar...

BioMarker Strategies, LLC

BioMarker Strategies has developed SnapPath®, the only cancer diagnostics system that automates and standardizes functional ex vivo profiling of live solid tumor cells from fre...

BioMarker Strategies

BioMarker Strategies (www.biomarkerstrategies.com) is a cancer diagnostics company that is developing a novel biomarker testing system to improve the treatment of cancer. SnapPath...

ABL, Inc. and Aushon BioSystems

Aushon BioSystems, Inc. is leading the way in protein biomarker discovery, development and analysis. Through the unique combination of proprietary microarray printing, extensive b...

BiomarkerBase

BiomarkerBase™ (http://www.biomarkerbase.com) includes every molecular biomarker on a drug label, every biomarker in a PMA-approved diagnostic, prognostic, or companion diagn...

More Information about "BioMarker Strategies, LLC" on BioPortfolio

We have published hundreds of BioMarker Strategies, LLC news stories on BioPortfolio along with dozens of BioMarker Strategies, LLC Clinical Trials and PubMed Articles about BioMarker Strategies, LLC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of BioMarker Strategies, LLC Companies in our database. You can also find out about relevant BioMarker Strategies, LLC Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...


Corporate Database Quicklinks



Searches Linking to this Company Record